<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117667">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908569</url>
  </required_header>
  <id_info>
    <org_study_id>IVISEV-004ROVIC</org_study_id>
    <nct_id>NCT01908569</nct_id>
  </id_info>
  <brief_title>Application of MACS and Time-lapse Technology in Good-prognosis Patients</brief_title>
  <official_title>Application of MACS (Magnetic-activated Cell Sorting) and Time-lapse Technology (Embryoscope) in Assisted Reproduction Patients With Good Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Sevilla</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MACS technique (magnetic-activated cell sorting) is based on the usage of microbeads,
      magnetic particles with a diameter of 35 nanometers joined to the compound annexin V.
      Annexin V is a protein with a high affinity for the molecule phosphatidylserine. This system
      allow us to eliminate those spermatozoids which have begun the apoptosis and have
      phosphatidylserine residues on their membrane surface. Using this technique, the apoptotic
      spermatozoids will join the microbeads and consequently be retained in a column applying a
      magnetic field.

      Recent studies show the benefits of spermatozoid selection using MACS and the improvement in
      mobility, viability, DNA fragmentation and fertilization potential. It has also been
      observed an improvement in the embryo cells division rate, clinical pregnancy rates and
      spermatozoid survival after thawing. However, it is necessary to perform new clinical
      studies in order to evaluate the real potential of this technology and its safety.

      The purpose of this study is to evaluate the effect of the MACS technique on the clinical
      results of good-prognosis patients who are going through IVF/ICSI treatments in order to
      achieve a pregnancy.

      The hypothesis of this study is that the application of the MACS technique in assisted
      reproduction treatments is associated with a better embryo quality and pregnancy rates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>14 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>14 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>14 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to ASEBIR criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>14 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>MACS Technique Efficacy</condition>
  <arm_group>
    <arm_group_label>NO MACS  + Time-lapse technology</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MACS + time-lapse technology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MACS</intervention_name>
    <description>The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.</description>
    <arm_group_label>MACS + time-lapse technology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO MACS</intervention_name>
    <description>The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.</description>
    <arm_group_label>NO MACS  + Time-lapse technology</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;38 years

          -  &gt;10 follicles with a diameter of ≥10 mm the day before the follicular puncture

        Exclusion Criteria:

          -  Patients subject to preimplantation genetic diagnosis treatments
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Blasco, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>IVI Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rocío Quiroga, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina González, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IVI Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cinzia Caligara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IVI Sevilla</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Blasco, MSc</last_name>
    <phone>+34954286274</phone>
    <email>victor.blasco@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolás Prados, PhD</last_name>
    <phone>+34954286274</phone>
    <email>nicolas.prados@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Seville</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Blasco, MSc</last_name>
      <phone>+34954286274</phone>
      <email>victor.blasco@ivi.es</email>
    </contact>
    <contact_backup>
      <last_name>Nicolás Prados, PhD</last_name>
      <phone>+34954289274</phone>
      <email>nicolas.prados@ivi.es</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Blasco, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Quiroga, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cinzia Caligara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina González, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>July 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MACS, time-lapse, embryo, spermatozoid, sperm</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
